ZED1227 not checked

Dr. Falk Pharma GmbH · TAK-227

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“oral treatment with different daily doses of ZED1227 vs placebo”In the company’s words, NCT07298343 on ClinicalTrials.gov
Tested for
Celiac Disease
Main trialPhase 2
“A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet”In the company’s words, NCT07298343 on ClinicalTrials.gov
Other names
TAK-227

Other drugs for Celiac Disease

All 6 drugs for Celiac Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Aug 2027 Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
Phase 2Completed 7 Jun 2023 Different Doses of ZED1227 vs. Placebo in NAFLD
Phase 1Completed 19 Jun 2023 A Study of TAK-227 in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow ZED1227

Following is part of Solo: you see every change to ZED1227 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in